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Abstract
Introduction: Events normally taking place in the terminal chondrocyte differentiation in the growth plate are also
observed during osteoarthritis (OA) development, suggesting that molecules, such as Wnts and bone
morphogenetic proteins (BMPs) regulating chondrocyte activity in the growth plate, may play a key role in
osteoarthritis pathogenesis. The aim of the study was to investigate the possible cross-talk between BMP-2 and
Wnt/b-catenin pathways in OA progression.
Methods: Low-density-lipoprotein receptor-related protein 5 (LRP-5) and 6, BMP-2, -4, and -7, bone morphogenetic
protein receptor-IA and IB (BMPR-IA and BMPR-IA), lymphoid enhancer factor-1 (LEF-1), and transcription factor 4
(TCF-4) expression levels were investigated in normal and osteoarthritic chondrocytes. LRP-5, b-catenin (phospho
and active form), matrix metalloproteinases (MMPs) 7, 9, 13, 14, ADAMTS-4, 5, as well as collagen X (COL10A1)
expression levels were evaluated after LRP-5 silencing in BMP-2-treated chondrocytes. The investigation of Smad1/
5/8 binding to LRP-5 promoter was assessed with chromatin immunoprecipitation (ChIP). Furthermore, we
evaluated the effect of experimental activation of the Wnt/b-catenin pathway with LiCl and LEF-1 silencing, in LiCl-
treated chondrocytes, on matrix metalloproteinases (MMPs) 7, 9, 13, 14, ADAMTS-4, 5, and collagen X (COL10A1)
expression, as well as possible interactions between LEF-1 and MMPs and COL10A1 promoters by using a ChIP
assay.
Results: LRP-5, BMP-2, BMP-4, BMPR-IA, and LEF-1 mRNA and protein expression levels were found to be
significantly upregulated in osteoarthritic chondrocytes compared with normal. We showed that treatment of
cultured chondrocytes with BMP-2 resulted in increased b-catenin nuclear translocation and LRP-5 expression and
that the BMP-2-induced LRP-5 upregulation is mediated through Smad1/5/8 binding on LRP-5 promoter. LRP-5
silencing reduced nuclear b-catenin protein levels, MMPs and collagen X expression, whereas increased phospho-b-
catenin protein levels in BMP-2-treated chondrocyte. Furthermore, we demonstrated that activation of the Wnt/b-
catenin signaling pathway by LiCl and LEF-1 downregulation by using siRNA regulates MMP-9, 13, 14, ADAMTS-5,
and COL10A1 expression, evidenced by the observed strong binding of LEF-1 to MMP-9, 13, 14, ADAMTS-5 and
COL10A promoters.
Conclusions: Our findings suggest, for the first time to our knowledge, that BMP-2-induced Wnt/b-catenin
signaling activation through LRP-5 may contribute to chondrocyte hypertrophy and cartilage degradation in
osteoarthritis.
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Introduction
Osteoarthritis (OA) is a progressively degenerative joint
disorder characterized by extracellular matrix degrada-
tion, articular cartilage loss, and osteophyte formation
[1]. It is considered a major health problem worldwide,
causing chronic disability in elderly people [2]. However,
the molecular mechanisms underlying OA pathogenesis
are poorly understood, and no disease-modifying ther-
apy is currently available [1,2].
Osteoarthritis involves mainly the dysfunction of articu-
lar chondrocytes, which leads to cartilage degradation
through chondrocyte maturation and MMPs production
[3,4]. In growth-plate chondrogenesis, chondrocytes
become hypertrophic, expressing collagen X, remove the
collagen matrix through the production of MMP-13, and
finally die by apoptosis and are replaced by bone [5,6].
Alternatively, chondrocytes of permanent cartilage reside
at the ends of the long bones and do not mature into the
hypertrophic state, preventing terminal differentiation by
an unknown mechanism [7]. However, during osteoarthri-
tis, chondrocytes lose the stable phenotype and undergo
changes that occur in terminal differentiated growth-plate
chondrocytes, such as high expression of MMP-13 and
collagen X [8-10].
The function of articular chondrocytes is regulated by
different growth factors, including Wnt ligands and
BMPs, which have been shown to play a critical role in
chondrocyte proliferation, differentiation, and apoptosis
[11-13]. The canonic or Wnt/b-catenin pathway signals
through Frizzled family receptors and coreceptors LRP-
5/LRP-6 and leads to stabilization of b-catenin, which in
turn interacts with transcription factors, such as LEF-1/
TCF-4 proteins, and activates specific genes, as c-myc
and cyclin D1 [14]. The role οf Wnt/b-catenin signaling
pathway in OA development has been previously sug-
gested, as an association has been reported between hip
OA susceptibility in women and two functional genetic
variants in FRZB, which encode frizzled-related protein,
a soluble antagonist of the Wnt canonic signaling path-
way [15-17]. Additional evidence for the involvement of
Wnt/b-catenin signaling in OA comes from the observa-
tion that frzd knockout mice are more susceptible to
chemically induced OA [18]. Besides FRZB, another
antagonist of the pathway, dickkopf-related protein 1
(Dkk-1), has been also shown to be associated with
reduced progression of OA in elderly women when it is
present in elevated levels in the serum [19]. A recent
study showed the implication of SOST, a potent inhibi-
tor of canonic Wnt signaling by binding to LRP5/6 in
OA disease processes with opposing effects by promot-
ing disease-associated subchondral bone sclerosis and
inhibiting degradation of cartilage [20]. Recently, we
showed that coreceptor of the Wnt/b-catenin signaling
pathway, LRP-5, may have a catabolic role in osteoar-
thritis, as we observed significant upregulation of LRP-5
expression in osteoarthritic chondrocytes [21]. More-
over, the involvement of the Wnt/b-catenin signaling
pathway in the regulation of cartilage development and
homeostasis has been confirmed, as increased expression
levels of several Wnt proteins and Frizzled receptors
have been found in the synovial tissue of arthritic carti-
lage [22], and the conditional activation of the b-catenin
gene in articular chondrocytes in adult mice leads to
premature chondrocytes differentiation and the develop-
ment of an OA-like phenotype [23]. Increased levels of
b-catenin have been reported in chondrocytes within
areas of degenerative cartilage, and its accumulation and
transcriptional activity has been shown to stimulate
chondrocyte matrix catabolic action, to induce the
expression of different MMPs in articular chondrocytes,
and to promote hypertrophic differentiation of chondro-
cytes, evidenced by increased expression of collagen X
[24-26].
Besides the Wnt/b-catenin pathway, BMPs also play a
significant role in chondrocyte differentiation. BMP sig-
naling is initiated by BMPs binding to their receptor
(BMPR-I and II), resulting in increased phosphorylation
of downstream signaling molecules, including Smad1,
Smad5, and Smad8 (R-Smads). The R-Smads form com-
plexes with Smad-4 and translocate into the nucleus,
where they bind to regulatory regions of target genes reg-
ulating their expression [27]. Although BMPs are consid-
ered to have a protective effect in articular cartilage, it
has been proposed that they are also involved in chon-
drocyte hypertrophy and matrix degradation [28-31].
Chen et al. [32] reported BMP-2, 4-6, and 11 mRNA
expression in normal and osteoarthritic adult human car-
tilage, whereas Steinert et al. [33] showed that BMP-2
and BMP-4 induce hypertrophy during the in vitro chon-
drogenic differentiation of human mesenchymal stem
cells. Moreover, in preosteoblastic cells, BMP-2 was
found to increase nuclear b-catenin protein levels and
induce the expression of different Wnts, suggesting the
interaction between Wnt and BMP-2 signaling during
osteoblastic differentiation [34].
As activation of Wnt/b-catenin and BMP-2 signaling
pathways may signify a causal relation to chondrocyte
differentiation and matrix degradation, we sought to
investigate the possible cross-talk between BMP-2 and
Wnt/b-catenin pathways in the catabolic action and
hypertrophy of osteoarthritic chondrocytes.
Materials and methods
Bioinformatic analysis
Promoter sequences of MMP-7, 9, 13, 14, ADAMTS-5,
4, and COL10A1 genes were obtained from CHIP
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Bioinformatics Tools [35]. For each of these genes, we
scanned the region from 1,500 base pairs upstream of
the transcript start to 100 base pairs downstream of the
coding-sequence start to find putative LEF-1 binding
elements (5’-CTTTGWW-3’). In addition, LRP-5 pro-
moter was tested for Smad binding sites (SBEs, 5’-
GCCGnGCG-3’).
Patients and cartilage samples
Articular cartilage samples were obtained from femoral
condyles and tibial plateaus of patients with primary
osteoarthritis undergoing knee-replacement surgery at
the Orthopaedics Department of University Hospital of
Larissa. In total, 18 patients were included in this study
(15 women/three men; mean age, 64.7 ± 9.7 years). All
osteoarthritic specimens had Mankin scores of 10 to 14.
Radiographs were obtained before surgery and graded
according to the Kellgren-Lawrence system. All patients
had K/L scores ≥ 2. The radiographs were assessed by
two independent observers who were blinded to all data
of the individuals. Normal articular cartilage was
obtained from nine individuals (four women/five men;
mean age, 44.6 ± 7.6 years) with 0 Mankin score, under-
going fracture-repair surgery, with no history of joint dis-
ease. Patients with rheumatoid arthritis and other
autoimmune diseases, as well as chondrodysplasias, infec-
tion-induced OA, and posttraumatic OA, were excluded
from the study. Written informed consent was obtained
from all individuals in the study. The study protocol con-
formed to the ethical guidelines of the 1975 Declaration
of Helsinki, as reflected in a priori approval by the Local
Ethical Committee of the University Hospital of Larissa.
Primary cultures of normal and osteoarthritic human
articular chondrocytes
Articular cartilage was dissected and subjected to sequen-
tial digestion with 1 mg/ml proteinase mixture (Pronase;
Roche Applied Science, Mannheim, Germany) and 1 mg/
ml collagenase P (Roche Applied Science, Mannheim,
Germany). Chondrocytes were counted and checked for
viability by using trypan blue staining. More than 95% of
the cells were viable after isolation. Isolated chondrocytes
from individual specimens were separately cultured with
Dulbecco Modified Eagle Medium/Ham F-12 (DMEM/F-
12) (GIBCO BRL, Paisley, UK) plus 5% fetal bovine
serum (FBS; Invitrogen, Life Technologies, Paisley, UK)
at 37οC under a humidified 5% CO2 atmosphere until
reaching confluence for 4 to 6 days.
RNA extraction and quantification of mRNA expression
Total cellular RNA was extracted from cultured chon-
drocytes by using Trizol reagent (Invitrogen, Life Tech-
nologies, Paisley, UK). Preservation of 28S and 18S
ribosomal RNA (rRNA) species was used to assess RNA
integrity. All the samples included the study had promi-
nent 28S and 18S rRNA components. The yield was quan-
tified spectrophotometrically. Transcription of 0.1 μg RNA
to cDNA was performed by using SuperScript III reverse
transcriptase (Invitrogen, Life Technologies, Paisley, UK)
and random primers (Invitrogen, Life Technologies, Pais-
ley, UK). Quantification of COL2A1, COL10A1, aggrecan,
MMP-13, LRP-5, LRP-6, BMP-2, BMP-4, BMP-7, BMPR-
IA, BMPR-IB, LEF-1, and TCF-4 mRNA expression was
performed with real-time PCR (ABI 7300; Applied Bio-
systems, Foster City, CA, USA). Reactions were done in
triplicate by using 2 μl of cDNA per reaction. All primers
used are shown in Table 1. Real-time PCR validation
was carried out by using the 2-ΔΔCT method. Normalized
gene-expression values for each gene based on cycle
threshold (CT) values for each of the genes and the house-
keeping gene glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) were generated.
Protein extraction and Western blot analysis
Chondrocytes were lysed by using RIPA buffer and a
cocktail of protease and phosphatase inhibitors. Protein
concentration was quantified by using the Bio-Rad Brad-
ford protein assay (Bio-Rad Protein Assay; BioRad, Her-
cules, CA, USA) with bovine serum albumin as standard.
Cell lysates from normal and OA chondrocytes were
electrophoresed and separated on a 4% to 20% Tris-HCl
gel (Bio-Rad, Hercules, CA, USA) and transferred to a
Hybond-ECL nitrocellulose membrane (Amersan Bios-
ciences, Piscataway, NJ, USA). The membrane was
probed with anti-LRP-5 (sc-21389; Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), BMP-2 (sc-57040; Santa
Cruz Biotechnology, Santa Cruz, CA, USA), BMP-4
(AF757, R&D Systems, Minneapolis, MN, USA) BMPR-
IA (sc-134285; Santa Cruz Biotechnology, Santa Cruz,
CA, USA), LEF-1 antibody (sc-8591; Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), and phospho-b-catenin
(9561; Cell Signaling Technology, Boston, MA, USA),
and signals were detected by using immunoglobulin
(IgG) conjugated with horseradish peroxidase (1:10,000
dilution). The results were normalized by using anti-b-
actin polyclonal antibody (Sigma-Aldrich, St. Louis, MO,
USA). The nitrocellulose membranes were then exposed
to photographic film, which was scanned, and the inten-
sities of the protein bands were determined with compu-
terized densitometry.
Immunohistochemistry
Cartilage specimens were fixed in 10% formalin overnight
and decalcified in 13% EDTA (Sigma-Aldrich, St. Louis,
MO, USA) for 3 weeks. Paraffin-embedded sections were
deparaffinized in xylene, dehydrated through graded alco-
hols, and placed in 3% H2O2 to block endogenous peroxi-
dase. Nonspecific staining was blocked with TBS
Papathanasiou et al. Arthritis Research & Therapy 2012, 14:R82
http://arthritis-research.com/content/14/2/R82
Page 3 of 14
containing 2% bovine serum albumin (BSA; Sigma-
Aldrich, St. Louis, MO, USA) for 1 hour at room tempera-
ture, followed by incubation with primary antibody BMP-
2 (c-57040; Santa Cruz Biotechnology, Santa Cruz, CA,
USA; 1:20 dilution with TBS containing 2% BSA) over-
night at room temperature. Normal serum of the same
species as the primary antibody was used as a control for
the primary antibody. After extensive washing with TBS,
the sections were incubated with horseradish peroxidase-
conjugated secondary antibody (Goat anti-Mouse; Invitro-
gen, Life Technologies, Paisley, UK; 1:250 dilution with
TBS containing 2% BSA) for 1 hour at room temperature
in a humid chamber. Finally, color reaction was performed
by using the substrate reagent 3,3’-diaminobenzidine tetra-
hydrochloride (DAB; Thermo Scientific, Rockford, IL,
USA). After being washed, the sections were incubated
with DAB and coverslipped with mounting medium.
Chondrocyte treatment with BMPs
Normal and osteoarthritic chondrocytes were seeded on
six-well plates at 3 × 105 cells/well, and 3 days after
seeding, cells were treated with 50 ng/ml of BMP-2 or
BMP-4 for 12, 24, and 48 hours; each experiment was
conducted in triplicate wells. RNA was extracted, and
real-time PCR analysis for osteocalcin, LRP-5, and LRP-
6 was performed, as described earlier. All primers used
are shown in Table 1. Cell lysates were extracted, and
LRP-5 (sc-21389; Santa Cruz Biotechnology, Santa Cruz,
CA, USA), phospho-b-catenin (9561; Cell Signaling
Technology, Boston, MA, USA), and total b-catenin
protein levels (9582; Cell Signaling Technology, Boston,
MA, USA) were evaluated by using Western blot analy-
sis, as described earlier.
Chondrocyte treatment with LiCl
Normal and osteoarthritic chondrocytes were seeded on
six-well plates at 3 × 105 cells/well, and 3 days after
seeding, cells were treated with 20 mM LiCl (Sigma-
Aldrich, St. Louis, MO, USA) for 12, 24, and 48 hours;
each experiment was conducted in triplicate wells. RNA
was extracted, and real-time PCR analysis for MMP-7,
9, 13, 14, ADAMTS-4, 5, and collagen X was performed
as described earlier. All primers used are shown in
Table 1. Cell lysates were extracted, and phospho-b-
catenin protein levels were evaluated by using Western
blot analysis, as described earlier.
Chromatin immunoprecipitation (ChIP) assay
ChIP was performed by using a ChIP assay kit (Upstate
USA, Inc., Charlottesville, VA, USA) on BMP-2-treated,
LiCl-treated, and untreated normal chondrocytes, as
previously described [21]. The cell lysates after treat-
ment with BMP-2 or LiCl were precleared by incubation
with G-Sepharose beads and were incubated with mono-
clonal antibody Smad-1/5/8 (Cell signaling Technology,
Boston, MA, USA) or polyclonal antibody LEF-1 over-
night at 4°C, respectively. Antibody to human purified
IgG was used as control (R&D Systems, Minneapolis,
MN, USA). The immunoprecipitated DNAs were used
for PCR amplification. All primers were designed
according to the nucleotide sequence of the gene pro-
moters, and each PCR fragment covered 250 to 400 bp
Table 1 Oligonucleotide primers used in real-time PCR assay
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of the promoter. Table 2 shows only the primer sets
that amplify the promoter region containing putative
sites, as observed after ChIP assay. The PCR products
were fractionated on 3% agarose gels and were stained
with ethidium bromide.
Oligonucleotide transfections
Normal and osteoarthritic chondrocytes were seeded in
six-well plates in DMEM/F-12 containing 5% FBS. After
overnight incubation, cells were transfected with specific
siRNA against LRP-5 (Ambion, Life Technologies, Paisley,
UK), LEF-1 (Invitrogen, Life Technologies, Paisley, UK),
and scrambled siRNA (used as a control; Invitrogen, Life
Technologies, Paisley, UK) by using LipofectAMINE 2000
(Invitrogen, Life Technologies, Paisley, UK), as described
by the manufacturer. No cell toxicity was detected from
the transfection agent. Four hours after siRNA transfec-
tion, the medium was changed, and cells were treated with
50 ng/ml BMP-2 (cultures with siRNA against LRP-5) or
20 mM LiCl (cultures with siRNA against LEF-1) for 48
hours. In each experiment, the results from three of the
six-well plates were averaged and considered as n = 1. No
significant variance was observed among the individual
wells in each averaged group. RNA was extracted, and
real-time PCR analysis for MMP-7, 9, 13, 14, ADAMTS-4,
5, and collagen X was performed, as described earlier.
Moreover, cell lysates were extracted, and phospho- as
well as total b-catenin protein levels were evaluated in
BMP-2-treated chondrocytes after LRP-5 siRNA transfec-
tion by using Western blot analysis, as described earlier.
Statistical analysis
Statistical significance was determined by using the Stu-
dent t test with a confidence level of 95% (P < 0.05).
Results
COL2A1, COL10A1, aggrecan, and MMP-13 expression in
normal and osteoarthritic chondrocytes
To evaluate differences in chondrocyte differentiation-
related genes, we evaluated COL2A1, COL10A1, aggrecan,
and MMP-13 mRNA expression levels in normal and
osteoarthritic chondrocytes. We found that COL2A1 and
aggrecan were significantly upregulated in normal
chondrocytes (P < 0.05; Figure 1), whereas COL10A1 and
MMP-13 were significantly upregulated in osteoarthritic
chondrocytes (P < 0.05; Figure 1).
LRP-5, BMP-2, BMP-4, BMP-7, BMPR-IA, BMPR-IB, LRP-6,
phospho-b-catenin, LEF-1, and TCF-4 expression in
normal and osteoarthritic chondrocytes
To investigate the involvement of BMP-2 and Wnt/b-
catenin signaling pathway in osteoarthritis, we evaluated
BMP-2, BMP-4, BMP-7, BMPR-IA, BMPR-IB, LRP-5,
LRP-6, phospho-b-catenin, LEF-1, and TCF-4, the major
transcription factors of the Wnt canonic signaling path-
way expression levels in normal and osteoarthritic chon-
drocytes. We found that osteoarthritic chondrocytes had
significantly higher LRP-5, BMP-2, BMP-4, BMPR-IA,
LEF-1 mRNA, and protein expression compared with
normal (P < 0.05; Figure 2a, b, c). Moreover, BMP-2 was
found to be upregulated in osteoarthritic compared with
normal cartilage after immunohistochemistry (Figure 2d).
Western blot analysis showed a significant reduction of
phospho-b-catenin protein levels in osteoarthritic chon-
drocytes compared with normal (P < 0.05; Figure 1e and
1f). No significant difference was found in LRP-6, BMP-
7, BMPR-IB, and TCF-4 mRNA levels between normal
and osteoarthritic chondrocytes (Figure 2a).
BMP-2 modulates Wnt/b-catenin signaling pathway
through stimulation of LRP-5 mRNA and protein
expression in chondrocytes
BMP-2 and Wnt/b-catenin signaling pathways have been
reported to play a significant role in the control of chon-
drocyte differentiation in the growth plate. We examined
Figure 1 COL2A1, COL10A1, aggrecan, and matrix
metalloproteinase (MMP)-13 expression in normal and
osteoarthritic chondrocytes. Quantitative COL2A1, COL10A1,
aggrecan, and MMP-13 expression in normal and osteoarthritic
chondrocytes. The results showed that COL2A1 and aggrecan were
significantly upregulated in normal chondrocytes, whereas COL10A1
and MMP-13 were significantly upregulated in osteoarthritic
chondrocytes. (Error bars, SEM; *P < 0.05).
Table 2 Oligonucleotide primers used for ChIP assay
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Figure 2 Low-density-lipoprotein receptor-related protein (LRP)-5, BMP-2, BMP-4, BMP-7, BMPR-IA, BMPR-IB, LRP-6, phospho-b-
catenin, LEF-1, and TCF-4 expression in normal and osteoarthritic chondrocytes. (a) Quantitative LRP-5, BMP-2, BMP-4, BMP-7, BMPR-IA,
BMPR-IB, LRP-6, LEF-1, and TCF-4 expression in normal and osteoarthritic chondrocytes. The results showed that LRP-5 (fourfold), BMP-2 (fourfold),
BMP-4 (threefold), BMPR-IA (twofold), and LEF-1 (4.5-fold) mRNA expression was significantly increased in osteoarthritic chondrocytes compared
with normal. (Error bars, SEM; standard errors, *P < 0.05). (b) LRP-5, BMP-2, BMP-4, BMPR-IA, and LEF-1 protein expression in normal and
osteoarthritic chondrocytes after Western blot analysis. The results showed that LRP-5, BMP-2, BMP-4, BMPR-IA, and LEF-1 protein expression was
significantly increased in osteoarthritic chondrocytes compared with normal. b-actin was used as internal control. (c) Bar graph showing the LRP-
5, BMP-2, BMP-4, BMPR-IA, and LEF-1 protein levels in normal (n = 5) and osteoarthritic chondrocytes (n = 11). (Error bars, SEM; standard errors,
*P < 0.05). (d) Expression of BMP-2 in normal and osteoarthritic cartilage after immunohistochemistry experiments. (e) Western blot analysis
showed a significant reduction of phospho-b-catenin protein levels in osteoarthritic chondrocytes compared with normal. (f) Bar graph showing
the phospho-b-catenin protein levels in normal (n = 5) and osteoarthritic chondrocytes (n = 11). (Error bars, SEM; *P < 0.05).
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the effect of BMP-2 on Wnt/b-catenin signaling-pathway
activation after treatment with BMP-2 in normal and
osteoarthritic chondrocytes. We found that BMP-2 treat-
ment at 12, 24, and 48 hours increased the active form of
nuclear b-catenin protein levels (Figure 3b), decreased
phospho-b-catenin protein levels (Figure 3b), and signifi-
cantly upregulated LRP-5 mRNA and protein expression,
but not LRP-6 (P < 0.05; Figure 3a and 3c). However, no
difference was noted in the active form of nuclear b-cate-
nin protein levels after treatment with BMP-4 (Figure 3d).
Further to investigate the intracellular signaling pathway
involved in BMP-2-induced LRP-5 expression, we sub-
jected BMP-2-treated chondrocytes to chromatin immu-
noprecipitation by using an antibody against Smad-1/5/8
and tested whether Smads bind to LRP-5 promoter via
Smad-binding elements and subsequently LRP-5 expres-
sion. We observed that LRP-5 promoter contains con-
served a Smad-binding site in -280 to -270 from the ATG
initiation codon, and Smad1/5/8 binding was enhanced
after treatment with BMP-2. Smads binding to osteocalcin
promoter served as positive control (Figure 3e).
LRP-5 upregulation by BMP-2 contributed to catabolic
activity and hypertrophy of osteoarthritic chondrocytes
To provide evidence that BMP-2 stimulates catabolic
enzymes and hypertrophic markers through Wnt/b-cate-
nin signaling in osteoarthritic chondrocytes, we blocked
LRP-5 mRNA expression by using siRNA against LRP-5 in
BMP-2-treated normal and osteoarthritic chondrocytes
and evaluated different MMPs (MMP-7, 9, 13, and 14),
ADAMTSs (ADAMTS-4 and 5), and collagen X expres-
sion levels. siRNA against LRP-5 effectively inhibited LRP-
5 expression, as we observed a downregulation of LRP-5
mRNA and protein expression in si-RNA-transfected
chondrocytes compared with the untransfected and the
scrambled siRNA-transfected chondrocytes 24 hours after
siRNA transfection (P < 0.05; Figure 4a). Moreover, we
found that LRP-5 silencing in BMP-2-treated normal and
osteoarthritic chondrocytes resulted in downregulation of
b-catenin protein levels (Figure 4b) and MMPs (MMP-9,
13, and 14), ADAMTS-5, and collagen X mRNA levels
(Figure 4d). In addition, phospho-b-catenin protein levels
were upregulated after LRP-5 siRNA transfection in BMP-
2-treated normal and osteoarthritic chondrocytes (Figure
4c), suggesting that LRP-5 upregulation by BMP-2 con-
tributed to Wnt/b-catenin signaling activation and chon-
drocyte catabolic activity and hypertrophy.
Effect of activation of the Wnt/b-catenin signaling
pathway by LiCl on the expression of genes implicated in
catabolic action and hypertrophy of chondrocytes
To obtain direct evidence that the Wnt/b-catenin signaling
pathway can trigger extracellular matrix degradation and
hypertrophic chondrocyte differentiation in osteoarthritis,
we activated the pathway in vitro by using LiCl in normal
and osteoarthritic chondrocytes and evaluated the expres-
sion levels of basic catabolic (MMP-7, 9, 13, 14, ADAMTS-
5, and 4) and hypertrophic markers (collagen X). We found
that normal and osteoarthritic chondrocyte treatment with
LiCl reduced phospho-b-catenin levels (Figure 5), suggest-
ing the stabilization of b-catenin and the activation of Wnt
canonic signaling. We then investigated the expression of
different MMPs, ADAMTSs, and collagen X in treated and
untreated-LiCl normal and osteoarthritic chondrocytes.
We found that MMP-13 and MMP-9 mRNA levels were
significantly upregulated after LiCl treatment in normal
and osteoarthritic chondrocytes (P < 0.05), whereas MMP-
14, ADAMTS-5, and collagen X expression was signifi-
cantly upregulated in normal chondrocytes (P < 0.05) and
showed a trend to increase in osteoarthritic chondrocytes
(Figure 6a). siRNA against LEF-1 decreased MMP-13, 9,
and 14 mRNA levels in LiCl-treated normal and osteoar-
thritic chondrocytes (P < 0.05), whereas ADAMTS-5 and
collagen X mRNA expression was significantly downregu-
lated in LiCl-treated osteoarthritic chondrocytes (P < 0.05)
and showed a trend to decrease in LiCl-treated normal
chondrocytes (Figure 6a). However, MMP-7 and
ADAMTS-4 mRNA levels remained at the same levels
after LiCl treatment and LEF-1 silencing (Figure 6a). To
investigate whether LEF-1 binds to MMP-9, 13, 14,
ADAMTS-5, and COL10A1 promoters through conserved
LEF-1 binding sites and upregulates their expression, we
performed a ChIP assay in chondrocytes after treatment
with LiCl for 24 and 48 hours. ChIP assay revealed LEF-1
binding sites on MMP-9 (-737 to -733 from the ATG
initiation codon), MMP-13 (from -1142 to -1138), MMP-
14 (from -575 to -571), ADAMTS-5 (from -755 to -751),
and COL10A1 (from -784 to -781) promoters, and the
binding was stronger in treated-LiCl chondrocytes, as LiCl
stabilizes b-catenin active form and increases nuclear b-
catenin protein levels, enhancing thus the complex
between b-catenin and LEF-1 and the subsequent binding
on gene promoters, suggesting that these genes are Wnt
targets in adult articular cartilage (Figure 6b). No LEF-1
binding sites were observed in MMP-7 and ADAMTS-4
promoter in the region from 1,500 base pairs upstream of
the transcript start to 100 base pairs downstream of the
coding-sequence start (Figure 6b). LEF-1 binding to AXIN-
2 promoter served as positive control.
Discussion
Articular chondrocyte proliferation, expression of hyper-
trophy markers, and remodeling of the cartilage matrix
by proteases are among the main characteristics of
osteoarthritis [1]. Recent studies have shown that events
normally taking place in terminal chondrocyte differen-
tiation in the growth plate are also observed during OA
development, suggesting that signaling molecules, such
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Figure 3 Effect of BMP-2 treatment on b-catenin and LRP-5 expression. (a) Real-time PCR of LRP-5 and LRP-6 mRNA levels in the presence
and absence of BMP-2 (50 ng/ml) for 12, 24, and 48 hours in normal and osteoarthritic chondrocytes. Osteocalcin expression used as positive
control. (Error bars, SEM; *P < 0.05 versus control). (b) and (c) Representative Western blots of b-catenin, phospho-b-catenin, and LRP-5 protein
levels after treatment with 50 ng/ml BMP-2 for 12, 24, and 48 hours in normal and osteoarthritic chondrocytes. b-Actin was used as internal
control. (d) ChIP assay was performed by using anti-Smad1/5/8 antibody or irrelevant anti-immunoglobin G antibody as negative control in
untreated and BMP-2-treated chondrocytes for 48 hours. Input samples are total genomic DNAs used as control for the PCR. ChIP assay shows
binding of transcription factor Smad1/5/8 to the LRP-5 promoter in BMP-2-treated chondrocytes. Osteocalcin promoter used as positive control.
Papathanasiou et al. Arthritis Research & Therapy 2012, 14:R82
http://arthritis-research.com/content/14/2/R82
Page 8 of 14
Figure 4 Effect of BMP-2 treatment and LRP-5 silencing on b-catenin, matrix metalloproteinases (MMPs), and collagen X expression.
(a) The effects of siRNA against LRP5 on LRP5 mRNA and protein expression levels. (Error bars, SEM; *P < 0.05 siRNA-transfected cells versus
untransfected. (b) Detection of b-catenin protein expression levels by Western blot analysis after LRP-5 siRNA transfection in BMP-2-treated
normal and osteoarthritic chondrocytes. (c) Detection of phospho-b-catenin protein expression levels with Western blot analysis after LRP-5
siRNA transfection in BMP-2-treated normal and osteoarthritic chondrocytes. (d) Detection of MMPs, ADAMTSs, and collagen X expression levels
with real-time PCR after LRP-5 siRNA transfection in BMP-2-treated normal and osteoarthritic chondrocytes. (Error bars, SEM; *P < 0.05 BMP-2-
treated cells versus control. **P < 0.05 BMP-2 and LRP-5 siRNA-treated cells versus BMP-2-treated cells).
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as Wnts and BMPs, regulating chondrocytes activity in
the growth plate may play a key role in osteoarthritis
pathogenesis [7,8].
In the present study, we provide for the first time, to
our knowledge, evidence for a cross-talk between BMP-
2 and Wnt/b-catenin signaling pathways in osteoar-
thritic chondrocytes. Although BMPs are involved in all
phases of chondrogenesis affecting chondrocyte differen-
tiation and cartilage anabolism [28-30], recent studies
have shown that BMPs can also have harmful effects on
articular cartilage [31]. However, their role in osteoar-
thritis is not completely elucidated. We evaluated BMP-
2, 4, and 7, as well as their receptors, BMPR-IA and
BMPR-IA expression levels in osteoarthritic and normal
chondrocytes and found that osteoarthritic chondrocytes
exhibited significantly higher BMP-2, 4, and BMPR-IA
mRNA and protein levels, suggesting the involvement of
BMP signaling in osteoarthritis progression. Previous
studies have shown that BMP-2 can be activated by IL-1
and TNF-a in normal and osteoarthritic chondrocytes
[36] and that it can stimulate the synthesis of matrix
molecules and MMPs expression by modulation of
chondrocyte differentiation [37,38]. In addition, mice
deficient in type 1 receptors Bmpr1a or Bmpr1b in carti-
lage develop severe generalized chondrodysplasia,
demonstrating that BMP signaling is required for chon-
drocyte proliferation, survival, and differentiation [39].
It has been suggested that BMP-2 modulates b-catenin
signaling through stimulation of Wnts, LRPs, and
Frizzled receptors expression in mesenchymal cells and
osteoblasts [34,40]. To investigate the role of BMP-2 on
the Wnt/b-catenin signaling-pathway activation in
osteoarthritic chondrocytes, we evaluated b-catenin and
LRP-5 levels after treatment of normal and osteoar-
thritic chondrocytes with BMP-2. We observed that
BMP-2 enhances the nuclear-active form of b-catenin
protein levels, decreases phospho-b-catenin protein
levels, and increases LRP-5 mRNA and protein levels,
which were found significantly upregulated in osteoar-
thritic chondrocytes compared with normal. In addition,
blocking LRP-5 expression in osteoarthritic chondro-
cytes resulted in a significant decrease in MMP-13
expression, the basic catabolic enzyme of osteoarthritis
[21]. All of these findings suggest LRP-5 involvement in
the increased activation of Wnt/b-catenin signaling and
cartilage degradation in osteoarthritis. No difference was
observed in the nuclear-active form of b-catenin levels
in BMP-4-treated chondrocytes, providing evidence on
the Wnt/b-catenin signaling-pathway activation by
BMP-2 and not by BMP-4.
To investigate further the molecular mechanism
involved in the BMP-2-induced LRP-5 upregulation, we
examined the effect of BMP-2 through Smads binding
on LRP-5 promoter activity in chondrocytes. Chromatin
immunoprecipitation indicated that BMP-2 directly
modulates LRP-5 expression, as we found, for the first
time, that Smads complexes bind to SBEs on the LRP-5
promoter, suggesting the BMP-2 induced-Wnt/b-catenin
signaling-pathway activation through direct modulation
of LRP-5 expression. Previous studies have shown that
osteoblast differentiation and new-bone formation
require the interaction of BMP-2 and the Wnt/b-catenin
signaling pathway [41,42]. BMP-2-enhanced LRP-5
expression has a strong catabolic activity in chondro-
cytes, as LRP-5 silencing inhibited BMP-2-induced-b-
catenin protein levels, MMPs, and collagen X expres-
sion, whereas increased phospho-b-catenin protein
levels, providing evidence on the involvement of BMP-
2-modulated b-catenin signaling in OA progression.
The Wnt/b-catenin signaling pathway participates in
normal adult bone and cartilage biology and seems to
be involved in cartilage degeneration and subsequent
OA progression [43,44]. To determine whether changes
in the Wnt-signaling pathway are associated with
Figure 5 Effect of LiCl treatment on phospho-b-catenin protein levels. Phospho-b-catenin protein levels in normal and osteoarthritic
chondrocytes after treatment with 20 mM LiCl for 48 hours. The results showed that phospho-b-catenin protein levels were significantly
decreased in LiCl-treated normal and osteoarthritic chondrocytes compared with untreated. The results were normalized by using anti-b-actin
polyclonal antibody.
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osteoarthritis, we evaluated the expression levels of Wnt
transcription factors, LEF-1 and TCF-4, and phospho-b-
catenin in osteoarthritic and normal articular chondro-
cytes. We observed that LEF-1 mRNA and protein-
expression levels were significantly increased in osteoar-
thritic chondrocytes, whereas phospho-b-catenin protein
levels were significantly decreased in osteoarthritic
chondrocytes, suggesting the excessive activation of
canonic the Wnt-signaling pathway in osteoarthritis.
To test for a possible association between the LEF-1
transcription factor of the Wnt/b-catenin signaling path-
way and catabolic action, as well as hypertrophy in
osteoarthritic chondrocytes, we activated Wnt/b-catenin
signaling by using LiCl in cultured chondrocytes. LiCl is
Figure 6 Effect of LiCl treatment and LEF-1 silencing on matrix metalloproteinases (MMP)s, ADAMTSs, and collagen X expression. (a)
Detection of MMPs, ADAMTSs, and collagen X expression levels with real-time PCR after LEF-1 siRNA transfection in LiCl-treated normal and
osteoarthritic chondrocytes. (Error bars, SEM; *P < 0.05 LiCl-treated cells versus control; **P < 0.05 LiCl and LEF-1 siRNA-treated cells versus LiCl-
treated cells). (d) Occupancy of MMPs, ADAMTSs, and COL10A1 promoters in LiCl-treated and -untreated chondrocytes by LEF-1 with ChIP
analysis. Input chromatin used as positive control, and IgG, as negative control.
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often used to mimic canonic Wnt signaling, as it inhi-
bits GSK-3b, therefore stimulating downstream compo-
nents of the Wnt-signaling pathway in an LRP-5-
independent manner [45]. The activation of the canonic
Wnt-b-catenin signaling by LiCl is not modulated by
LRP-5 phosphorylation, and until now, differences in
phospho-LRP-5 protein levels between OA and normal
cartilage have not been reported. We observed that
experimental activation of Wnt/b-catenin signaling
induced significant upregulation of catabolic enzymes
such as MMP-9, 13, 14, aggregenases, as ADAMTS-5
and hypertrophic marker, collagen X. The upregulation
of the above genes takes place in a direct manner, as we
demonstrated, conserved LEF-binding sites in MMP-9,
13, 14, ADAMTS-5, and COL10A1 promoters, responsi-
ble for their promoter activity and is associated directly
with the b-catenin/LEF-1 complex. Moreover, LEF-1
downregulation using siRNA reduced MMPs,
ADAMTS-5, and collagen X mRNA expression, whose
levels increased after treatment with LiCl, providing
strong evidence of gene-expression regulation of cata-
bolic factors by LEF-1. No upregulation was observed in
MMP-7 and ADAMTS-4 levels, as no conserved LEF-
binding sites were found on their promoters. It has been
shown that Lef-1 binding to the 3’ region of mmp-13 is
involved in the transcriptional regulation of the mmp-13
gene in mouse chondrocytes [46]. It can be suggested
that the Wnt/b-catenin signaling pathway promotes
chondrocytes catabolic activity, degrading not only col-
lagen II, as evidenced by the observed increased expres-
sion of MMP-13 and 14, but also other extracellular
matrix molecules, such as fibronectin and aggrecan,
through enhancement of MMP-9 and ADAMTS-5
expression, respectively. It has been shown that MMP-9,
a gelatinase with broad substrate specificity, contributes
to fibronectin degradation and increases the fibronectin
fragments, which have been shown to be elevated in OA
[47,48], whereas ADAMTS-5, one of the most efficient
aggrecanases, degrades aggrecan, the major proteoglycan
in cartilage [49]. In additional studies in a murine model
of osteoarthritis, deletion of ADAMTS-5 provided sig-
nificant protection against proteoglycan degradation ex
vivo and decreased the severity of osteoarthritis [50].
We also found that the Wnt/b-catenin signaling path-
way contributes to the hypertrophic differentiation of
chondrocytes, increasing collagen X expression, the
basic hypertrophic marker of chondrocytes. We there-
fore showed that the Wnt/b-catenin signaling pathway
plays a major role in OA progression, as articular chon-
drocytes, after experimental activation of the Wnt/b-
catenin signaling pathway, cannot maintain the charac-
teristics of the permanent cartilage but instead enhance
extracellular matrix degradation, evidenced by increased
MMPs and ADAMTS-5 expression, and mature to
hypertrophic through stimulation of collagen X
expression.
Conclusion
In conclusion, we demonstrated, for the first time to our
knowledge, that the BMP-2-induced Wnt/b-catenin sig-
naling pathway activation through LRP-5 induces chon-
drocyte catabolic action and hypertrophy, providing thus
novel and direct evidence on the role of BMP-2
mediated by Wnt/b-catenin signaling in osteoarthritis
progression.
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